Drug Type Fusion protein |
Synonyms RC-28, RC-28-E, RC28-E |
Target |
Mechanism VEGF inhibitors(Vascular endothelial growth factor inhibitors), bFGF inhibitors(Fibroblast growth factor 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic macular oedema | Phase 3 | CN | 08 Jun 2023 | |
Wet age-related macular degeneration | Phase 3 | CN | 14 Mar 2023 | |
Nonproliferative diabetic retinopathy | Phase 2 | CN | 25 May 2021 |
Phase 1 | - | tnlkudocvi(hagmctithv) = Patients using Rongchang BioRC28 demonstrated good tolerability and safety, with significant improvements in vision and disease, and were effective in patients who had previously received anti-VEGF therapy and PCV (fundus polypoid choroidal vasculopathy). vbjkxhqqyf (ryeenuwxgs ) | Positive | 15 Sep 2022 | |||
Not Applicable | - | - | oexpikbxet(brlmnnwaln) = ixnmoghufq yzsdncnvxx (jcwbkmaezy ) View more | - | 01 Mar 2012 |